Bowen's FX Therapeutics was founded by Jeff Parr following the diagnosis of his grandson, Bowen Parr with full mutation Fragile X Syndrome and Jeff’s desire to find a cure for Bowen and all who have Fragile X. Our lead program is an engineered Fragile X Messenger Ribonucleoprotein (FMRP) replacement strategy in Lead Optimization, with an aim of selecting a clinical candidate in 2025.